Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02270931 · ClinicalTrials.gov registry record

A Prospective Longitudinal Breast Cancer Study

A clinical trial of Breast Cancer, sponsored by Fujirebio Diagnostics.

Completed
Registry status
130
Enrollment target
3
Study locations

NCT02270931: Completed study of Breast Cancer, sponsored by Fujirebio Diagnostics.

NCT02270931 is a study of Breast Cancer that has completed, run by Fujirebio Diagnostics. The registered enrollment target is 130 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (95% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02270931, a study of Breast Cancer, has completed, sponsored by Fujirebio Diagnostics.

COMPLETED
Registry status
130 participants
Enrollment target
3
Study locations

Study Summary

The purpose of this study is to obtain sufficient specimens and correlating clinical data from a well-controlled prospective clinical trial collecting longitudinal specimens from subjects diagnosed with any stage of breast cancer.

Primary Outcome

130 patients with Recurrence or Progressive Breast Cancer.

Conditions Studied

Interventions

  • DEVICE CA 15-3 Assay

Study Locations (3)

Florida

  • Jane Skelton, MD - Boca Raton
  • Broward Health Medical Center - Fort Lauderdale

North Carolina

  • New Hanover Regional Medical Center - Wilmington

Trial Details

FieldValue
Enrollment Target 130 participants
Start Date 2014-05
Est. Completion 2021-06-30
Fujirebio Diagnostics

13 total trials

What the finished NCT02270931 record still lists

NCT02270931 is an observational study that tracks outcomes without assigning an intervention. The registered 130 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (95% lower).

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which CA 15-3 Assay is the first listed.

NCT02270931 reports a single indexed study location in Florida, North Carolina.

Frequently Asked Questions

What is clinical trial NCT02270931 about?

NCT02270931 is a clinical study titled "A Prospective Longitudinal Breast Cancer Study". The purpose of this study is to obtain sufficient specimens and correlating clinical data from a well-controlled prospective clinical trial collecting longitudinal specimens from subjects diagnosed with any stage of breast cancer.

What is the current status of trial NCT02270931?

This trial is currently completed. The enrollment target is 130 participants. The study started on 2014-05. Estimated completion is 2021-06-30.

What conditions does trial NCT02270931 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT02270931?

The interventions under investigation include: CA 15-3 Assay (DEVICE).

Who is sponsoring clinical trial NCT02270931?

This trial is sponsored by Fujirebio Diagnostics, which has 13 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02270931 being conducted?

This trial has 3 study locations across Florida, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02270931's enrollment target sits among peer trials

130 489th of 1224 higher than 730 of 1,224 other Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01492036 · 130 participants

    Long-Term Follow-Up of Recipient of Gene Transfer Research

  • NCT01631617 · 130 participants · Phase 2

    Effects of Treatments on Atopic Dermatitis

  • NCT02368041 · 130 participants

    Utility of Thenar Near Infrared Spectroscopy (NIRS) in Pediatric Patients With Heart Failure

  • NCT02604277 · 130 participants · NA

    Suicidal Behavior in Patients Diagnosed With Bipolar Disorder

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02270931, the US trial registry maintained by the National Library of Medicine. NCT02270931 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.